GlassScriptPhysician profile
Roxanne Allen
NPI 1982292785
$6,942.32
in general payments reported to CMS, 2019-2025
30 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $441 · 2023: $2,992 · 2024: $2,060 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,345 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,345.28 |
| Education | $155.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,828.64 | 2022-2025 | |
| Janssen Biotech, INC. | $840.08 | 2023-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $584.95 | 2022-2025 | Entyvio, Gattex, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $554.63 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $430.70 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $377.45 | 2024-2025 | Voquezna |
| Celgene Corporation | $277.35 | 2023-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $170.29 | 2023-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $124.99 | 2023 | Stelara |
| Ferring Pharmaceuticals INC. | $115.10 | 2023 | Rebyota |
| Gilead Sciences, INC. | $114.73 | 2023 | Epclusa |
| Ardelyx, INC. | $53.93 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.78 | 2023 | Xifaxan |
| Impulse Dynamics (USA) INC. | $41.55 | 2024 | Optimizer |
| Lilly USA, LLC | $34.81 | 2024 | Omvoh |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $33.57 | 2024 | Ingrezza |
| Ucb, INC. | $31.08 | 2024 | Briviact |
| Intercept Pharmaceuticals, INC. | $28.31 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $27.27 | 2024 | |
| Genzyme Corporation | $25.94 | 2024 | |
| Upsher-Smith Laboratories LLC | $24.11 | 2022 | |
| Kci USA, INC. | $23.17 | 2023 | Prevena |
| Vivus LLC | $22.87 | 2024 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $22.43 | 2024 | Dupixent |
| Exact Sciences Corporation | $20.68 | 2025 | Cologuard Collection Kit |
| Intuitive Surgical, INC. | $20.48 | 2023 | Da Vinci Surgical System |
| Merck Sharp & Dohme LLC | $20.32 | 2023 | |
| Integra Lifesciences Corporation | $18.90 | 2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Braintree Laboratories, INC. | $14.73 | 2025 | Sutab, Suflave |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.